New treatment for lung injuries caused by sulfur mustard exposure
Official title: A Novel, Host-Directed Therapeutic for the Treatment of Sulfur Mustard Induced Lung Injury
Funded at Cmtx Biotech, INC. · NIH-11008227 · Data updated 2026-11-12
This study is testing a new oral medication called incyclinide to help people who have lung injuries from exposure to sulfur mustard, aiming to improve their breathing and overall recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cmtx Biotech, INC. NIH-funded |
| Lab location | 1 site (Kings Park, United States) |
| Project start | July 9, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $299,993 |
| NIH project number | 1R41AI187083-01 |
| Project ID | NIH-11008227 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced exposure to sulfur mustard and are suffering from related lung injuries.
✕Less likely to help
Patients who have not been exposed to sulfur mustard or who have other unrelated respiratory conditions may not benefit from this research.
What this research studies
This research focuses on developing a novel therapeutic approach using a small-molecule drug called incyclinide to treat lung injuries caused by exposure to sulfur mustard, a harmful chemical agent. The treatment aims to modulate the body's response to the injury rather than just addressing the symptoms. Patients who have been exposed to sulfur mustard may experience severe respiratory issues, and this research seeks to provide a new option for managing those complications. The approach involves administering the drug orally, which could make it more accessible for patients in need.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from lung injuries due to sulfur mustard exposure.
How similar studies have gone: While the approach of using host-modulatory therapies is promising, this specific application for sulfur mustard-induced lung injury is novel and has not been extensively tested in prior research.
Where this research is happening
-
Cmtx Biotech, INC.
Kings Park, United States Active
Researchers
- Principal investigator: Veress, Livia Agnes — Cmtx Biotech, INC.
- Study coordinator: Veress, Livia Agnes
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.